To use real world data to help identify trends across the clinical outcomes of all patients using chyme reinfusion therapy.
Determine the efficacy and safety of chyme reinfusion therapy and advance knowledge in the use and efficacy of chyme reinfusion therapy.
Pseudo-anonymised data can be accessed by The Insides Company to support the post market surveillance requirements for medical device manufacturers. Other requests for access to the pseudo-anonymised data from the chyme reinfusion therapy registry will be assessed on a case-by-case basis and will always require regulatory and ethical approval prior to access being granted.
The chyme reinfusion therapy registry is an observational registry; this means that the data that is recorded will be guided by the tests and treatment pathways chosen by the patients treating clinical team.
Patient data is entered into the registry in a pseudo-anonymised format and uses industry standard Amazon Web Servers with high level encryption. These processes comply with all data privacy laws relevant to the country where the data originates.
No data is entered into the registry until the relevant regulatory and ethical bodies in target countries have provided approval.
Reach out to The Insides Company to discuss the options for registry participation within your country.
Expanding knowledge around the use of chyme reinfusion therapy in intestinal failure patients.